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Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis
increasing mitochondrial O2ˉ· production in cancer cells
Marco Cordani1,2, Giovanna Butera1, Ilaria Dando1, Margalida Torrens-Mas3,4,5, Elena Butturini1, Raffaella Pacchiana1, Elisa Oppici1,
Chiara Cavallini6, Sara Gasperini7, Nicola Tamassia7, Mercedes Nadal-Serrano8,9, Michela Coan10, Davide Rossi11,12, Gianluca Gaidano13,
Michele Caraglia14, Sofia Mariotto1, Riccardo Spizzo10, Pilar Roca3,4,5, Jordi Oliver3,4,5, Maria Teresa Scupoli6 and Massimo Donadelli1
BACKGROUND: The TP53 tumor suppressor gene is the most frequently altered gene in tumors and mutant p53 gain-of-function
isoforms actively promote cancer malignancy.
METHODS: A panel of wild-type and mutant p53 cancer cell lines of different tissues, including pancreas, breast, skin, and lung
were used, as well as chronic lymphocytic leukemia (CLL) patients with different TP53 gene status. The effects of mutant p53 were
evaluated by confocal microscopy, reactive oxygen species production assay, immunoblotting, and quantitative reverse
transcription polymerase chain reaction after cellular transfection.
RESULTS:We demonstrate that oncogenic mutant p53 isoforms are able to inhibit SESN1 expression and consequently the amount
of SESN1/AMPK complex, resulting in the downregulation of the AMPK/PGC-1α/UCP2 axis and mitochondrial O2ˉ· production. We
also show a correlation between the decrease of reduced thiols with a poorer clinical outcome of CLL patients bearing mutant TP53
gene. The restoration of the mitochondrial uncoupling protein 2 (UCP2) expression, as well as the addition of the radical scavenger
N-acetyl-L-cysteine, reversed the oncogenic effects of mutant p53 as cellular hyper-proliferation, antiapoptotic effect, and resistance
to drugs.
CONCLUSIONS: The inhibition of the SESN1/AMPK/PGC-1α/UCP2 axis contributes to the pro-oxidant and oncogenic effects of
mutant p53, suggesting pro-oxidant drugs as a therapeutic approach for cancer patients bearing mutant TP53 gene.
British Journal of Cancer (2018) 119:994–1008; https://doi.org/10.1038/s41416-018-0288-2
BACKGROUND
Mutations in the TP53 gene occur in over 50% of the human
cancers and most of them are missense mutations that result in
the expression of mutant isoforms of the p53 protein,1 which can
acquire new biological properties referred as gain-of-function
(GOF). In addition to the loss of the tumor suppression function of
wild-type p53, GOF mutant p53 proteins contribute to the
maintenance and stimulation of cancer growth through the
acquisition of oncogenic functions.2,3 In many tumors, p53
mutations are associated with high genomic instability, poor
prognosis, reduced response to chemotherapy, promotion of
migration, invasion and metastasis, and accelerated tumor
recurrence.4–6 Different models have been proposed to explain
the GOF activities of mutant p53, including binding and
inactivation of the p53 family members p63 and p73, modulation
of the activity of a number of transcription factors, or the
inactivation of DNA damage molecular sensors.7–9 Our group
documented that DNA damaging in cancer cells by gemcitabine
drug stabilized the nuclear localization of mutant p53 proteins,
which in turn triggered the expression of cell cycle-related genes,
resulting in hyper-proliferation effects and ultimately chemoresis-
tance.10 In addition, we and others demonstrated that GOF
mutant p53 isoforms can alter cancer cell metabolism,11–14
autophagy response to various stimuli15,16 and cancer microenvir-
onment.17,18 This broad spectrum of molecular properties
indicates that GOF mutant p53 is involved in a plethora of
different cellular pathways focused on cancer progression and
aggressiveness.
Mitochondrial uncoupling protein 2 (UCP2) is an anion carrier
protein, which uncouples the oxidative phosphorylation (OXPHOS)
from ATP production by dissipating the proton gradient
generated across the mitochondrial inner membrane. This
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prevents the proton motive force from becoming excessive, thus
decreasing the formation of mitochondrial superoxide ions (O2ˉ·),
produced by leakage of electrons from the mitochondrial
transport chain.19 Importantly, the UCP2-mediated dissipation of
the proton gradient during OXPHOS confers an antioxidant role to
mitochondrial UCP2 proteins.20 It is well-established that eukar-
yotic cells have adopted many mechanisms in order to maintain a
correct balance between reactive oxygen species (ROS) generation
and their elimination by ROS-scavenging activities. Dysfunction of
any of these antioxidant mechanisms could lead to an increase of
intracellular ROS levels and alterations in the cellular redox status,
resulting in the aberrant stimulation/suppression of some crucial
signaling pathways. Indeed, increased ROS production can play a
role in a variety of pathological conditions, including cancer,
neurodegenerative diseases, and aging.21,22
Recently, some studies described that, in contrast to the
antioxidant role of wild-type p53, mutant p53 proteins can
stimulate ROS production. However, the precise molecular
mechanisms involved in this aberrant regulation of ROS by
mutant p53 isoforms are still incomplete. In the present study, we
report that GOF mutant p53 proteins inhibit SESN1 expression and
consequently the amount of the SESN1/AMPK complex, resulting
in the inhibition of AMPK signaling and of proliferator-activated
receptor gamma coactivator-1 alpha (PGC-1α)/UCP2 axis. We
demonstrate that AMPK/PGC-1α/UCP2 blockage is functionally
involved in the pro-oxidant role of mutant p53 in cancer cells
stimulating mitochondrial O2ˉ· production without damaging
mtDNA. We also disclose that UCP2 decrease and consequent
ROS increase are functionally associated to mutant p53 GOF,
determining hyper-proliferation, drug chemoresistance, and anti-
apoptotic effects in cancer cells.
MATERIAL AND METHODS
Drugs and chemicals
Gemcitabine (2’,2’-difluoro-2’-deoxycytidine; GEM) was provided
by Accord Healthcare (Milan, Italy) and solubilized in sterile bi-
distilled water. N-acetyl-L-cysteine (NAC) and CP-31398 dihy-
drochloride hydrate were obtained from Sigma-Aldrich (Milan,
Italy) and solubilized in bi-distilled sterile water. 5-
Aminoimidazole-4-carboxamide ribonucleotide (AICA-R) was pro-
vided by MERK Calbiochem (Darmstadt, Germany) and solubilized
in bi-distilled sterile water. RITA [5,5’-(2,5-furandiyl)bis-2-thiophe-
nemethanol; reactivation of p53 and induction of tumor cell
apoptosis] was obtained from Sigma-Aldrich and solubilized in
DMSO.
Cell culture
Pancreatic adenocarcinoma PaCa3 (WTp53), Panc1 (mutant p53-
R273H), and AsPC1 (p53-null) cell lines were grown in Roswell Park
Memorial Institute medium (Life Technologies, Milan, Italy),
whereas lung cancer H1299 (p53-null), melanoma A375 (WTp53),
MeWo (mutant p53-E258K), breast cancer MCF7 (WTp53), SKBr3
(mutant p53-R175H), MDA-MB-468 (mutant p53-R273H), and
MDA-MB-231 (mutant p53-R280K) cell lines were cultured in
Dulbecco's Modified Eagle's Medium (Life Technologies). All
culture media were supplemented with 10% fetal bovine serum
(FBS), and 50 µg/ml gentamicin sulfate (BioWhittaker, Lonza,
Bergamo, Italy). Cell lines were incubated at 37 °C with 5% CO2.
The list of the cell lines used in this study and their p53 status are
summarized in Table 1. PaCa3 cell line was kindly provided by Dr.
Aldo Scarpa (University of Verona, Italy) and all the other cell lines
were purchased by ATCC (Manassas, Virginia, USA). Pancreatic
ductal adenocarcinoma cells were previously characterized23 and
all the cell lines were routinely tested to confirm lack of
mycoplasma infection. The clones C9 (mock) and H1 (stably
expressing mutant p53-R273H) of the p53-null H1299 cells were
kindly provided by Dr. Riccardo Spizzo (Centro di Riferimento
Oncologico, National Cancer Institute, Aviano, Italy).
Cell proliferation assay
Cells were seeded in 96-well plates and the day after were
incubated with various compounds at the indicated conditions or
transfected with the indicated constructs (see figure legends). At
the end of the treatments, cell growth was measured by Crystal
Violet assay (Sigma-Aldrich) according to the manufacturer’s
protocol, and absorbance was measured by spectrophotometric
analysis (A 595 nm).
Liposome-mediated transient cell transfection
Cells were transfected as previously described.15 In brief, the
ectopic expression of mutant p53 in p53-null cancer cells was
carried out transfecting pcDNA3-mutp53R273H or pcDNA3-
mutp53R175H expression vectors, or their relative mock vector
(pcDNA3). Wild-type and mutant p53 protein expression was
transiently knocked-down by transfection with pRSUPER-p53
vector or its negative control (pRSUPER), kindly provided by Dr.
Agami (The Netherlands Cancer Institute, Amsterdam, Nether-
land). Commercial siRNA smart pool of three oligonucleotides
(sip53) transiently targeting p53 (Santa Cruz Biotech, Dallas, TX,
USA; sc-29435) was used in the real-time qPCR to exclude back
side effects and to confirm the robustness of the data. A siGFP as
non-silencing control (5′-GGCTACGTCCAGGAGCGCACC-3′) was
used as negative control. The ectopic expression of wild-type or
dominant negative (DN)-AMPK subunit γ2 was previously
described.24
UCP2 silencing was carried out with a specific siRNA-UCP2 (5′-
GCUAAAGUCCGGUUACAGATT-3′), and a non-targeting siRNA (5′-
CAGUCGCGUUUGCGACUGG-3′) was used as negative control
(Ambion, Thermo Fisher Scientific, Rockford, IL, USA). UCP2
overexpression was performed using a pCMV expression vector
containing the human complementary DNA of UCP2 (OriGene
Technologies, Rockville, MD, USA). Cells transfected with the
empty pCMV vector were used as a negative control (mock).
Knockdown of PGC-1α expression was obtained by transfecting
cells with a duplex siRNA-PGC-1α having the following sequences:
5′-ACAGUGAAUUUAAACGACAGCAGCU-3′ and 5′-AGCUGCUGUC
GUUUAAAUUCACUGU-3′ purchased from Life Technologies.
Lentivirus cell transduction
To silence mutant p53 expression, we used two different DNA
plasmids pLKO.1 puro vectors encoding TP53-shRNAs
(TRCN0000003756 or TRCN0000003753 Sigma-Aldrich) indicated
Table 1. Tissue of origin and p53 status of cancer cell lines
Cancer cell lines Tissue origin p53 status Mutation
PaCa3 Pancreas Wild-type None
MCF7 Breast Wild-type None
A375 Skin Wild-type None
Panc1 Pancreas Mutated R273H
PaCa44 Pancreas Mutated C176S
MDA-MB-468 Breast Mutated R273H
SkBr3 Breast Mutated R175H
MDA-MB-231 Breast Mutated R280K
MeWo Skin Mutated E258K
AsPC1 Pancreas Null Gene deleted
H1299 Lung Null Gene deleted
Mutant p53 blocks SESN1/AMPK/PGC-1α/UCP2 axis increasing mitochondrial. . .














as p53-SH1 or p53-SH2, respectively. As negative control we used
a non-target shRNA control (SHC016; Sigma-Aldrich) indicated as
p53-NT. To generate viral particles, 293FT were transfected using
one of the pLKO shRNA DNA vector together with ViraPower
Lentiviral Packaging Mix (pLP1, pLP2 and pLP/VSV-G) (Thermo
Fisher Scientific, Eugene, OR, USA). Seventy-two hours later, viral
supernatants were collected and transducing units per ml of
supernatant were determined by limiting dilution titration in cells.
A MOI (multiplicity of infection) of 5–1 (five transducing viral
particles to one cell) was used for transducing cells using
Polybrene (Sigma-Aldrich) at a final concentration of 8 μg/ml to
increase transduction efficiency. Twenty-four hours after transduc-
tion, puromycin selection was started and mutant TP53-silenced
cells were immediately used for experiments.
RNA isolation and quantitative real-time PCR analysis
Total RNA was extracted from cells using PureLink RNA Mini Kit
(Life Technologies, Milan, Italy) and reverse-transcribed at 37 °C for
50min in the presence of random hexamers and Moloney murine
leukemia virus reverse transcriptase (Life Technologies). Tran-
scripts were measured by real-time qPCR using the SYBR Green
assay (Applied Biosystems, Carlsbad, CA, USA) with a 7900 HT Fast
Real-Time PCR System (Thermo Fisher). PCR analysis was carried
out using specific oligonucleotides for the genes listed in
Supplementary Table 1. The average of cycle threshold of each
triplicate was analyzed according to the 2-ΔΔCt method. GAPDH
gene expression was used as endogenous control to standardize
mRNA expression. All reactions were performed in triplicate from
three independent experiments.
Immunoblot analysis
Cells were lysed in the presence of phosphatase and protease
inhibitors (50 mM Tris HCl pH 8, 150 mM NaCl, 1% Igepal CA-630,
0.5% Na-Doc, 0.1% sodium dodecyl sulphate (SDS), 1 mM Na3VO4,
1 mM NaF, 2.5 mM ethylenediaminetetraacetic acid (EDTA), 1 mM
phenylmethylsulfonyl fluorid, and 1 × protease inhibitor cocktail).
Protein extracts (50 μg/lane) were resolved on SDS-polyacrylamide
gel and electro-blotted onto polyvinylidene difluoride (PVDF)
membranes (Millipore, Milan, Italy). Primary antibodies against p53
(Santa Cruz Biotech, Dallas, Texas, USA, #sc-263), phospho (Ser15)
p53 (Cell Signaling Technology, Danvers, MA, USA; #9286),
phospho (Thr172)AMPK (Cell Signaling Technology, #2535), AMPK
(Cell Signaling Technology, #2603), SESN1 (GeneTex, Irvine, CA,
USA; #GTX118141), SESN2 (Santa Cruz Biotech, #sc-393195), PGC-
1α (Calbiochem, #ST1202), UCP2 (Abnova, Taipei City, Taiwan;
#PAB7242), GAPDH (Cell Signaling Technology, #5174 s), alpha-
tubulin (Oncogene, La Jolla, CA, USA; #CP06), and secondary anti-
mouse or anti-rabbit IgGs (Upstate Biotechnology, Milan, Italy)
horseradish peroxidase-conjugated antibodies were used. All
antibodies were diluted in 5% (w/v) non-fat milk or bovine serum
albumin (BSA) in TBS–Tween. The immunocomplexes were
visualized by chemiluminescent substrates (Amersham Pharmacia
Biotech, Milan, Italy) using the Chemidoc XRS Imaging System
(Bio-Rad Laboratories, Milan, Italy) and the intensity of the
chemiluminescence response was measured by processing the
image with NIH ImageJ software (http://rsb.info.nih.gov/nih-
image/).
Immunoprecipitation assay
Cells were lysed in radioimmunoprecipitation assay (RIPA) buffer
(20 mM Tris HCl, pH 8.0, 150 mM NaCl, 1% Nonidet P-40, 1 mM
EDTA, 10% glycerol, 100 µM NaF, 1 mM Na3VO4) supplemented
with protease cocktail inhibitor. For each immunoprecipitation, 2
μg of anti-mouse AMPKα antibody (Santa Cruz Biotech, #sc-
74461), anti-mouse SESN1 (PA26) antibody (Santa Cruz Biotech,
#sc-376170), or mouse IgG (Santa Cruz Biotech) as control were
used. Equal amounts of proteins from the clarified cell lysates were
incubated overnight with antibodies at 4 °C. The immune
complexes were collected by addition of protein A sepharose
(Millipore), rinsed extensively with RIPA buffer and eluted in a non-
reducing sample buffer (62.5 mM Tris HCl, pH 6.8, 10% glycerol,
5% SDS, 0.05% bromophenol blue). After electrophoresis on 10%
SDS–PAGE, proteins were transferred to PVDF membrane and
non-specific binding was blocked by incubation in 3% BSA diluted
in TBS–Tween. Membranes were then probed with anti-SESN1
(Santa Cruz Biotech, #sc-376170), anti-SESN2 (Santa Cruz Biotech,
#sc-393195), or with anti-AMPKα (Cell Signaling Technology,
#mAb-5831). After washing, blots were incubated with anti-
rabbit IgG peroxidase-conjugated antibody (Cell Signaling Tech-
nology) and protein–antibody reactions were detected with
chemiluminescent detection system (Immun-Star™ WesternC™
Kit, Bio-Rad) using the ChemiDoc XRS Imaging System (Bio-Rad
Laboratories).
Apoptosis assay
Cells were seeded in 96-well plates and 24 h later were treated as
indicated in figure legends. At the end of the treatments, cells
were fixed with 2% paraformaldehyde in phosphate-buffered
saline (PBS) for 30 min at room temperature, washed twice with
PBS and stained with annexin V/FITC (Bender MedSystem, Milan,
Italy) in binding buffer (10 mM HEPES/NaOH pH 7.4, 140mM NaCl,
and 2.5 mM CaCl2) for 10 min at room temperature in the dark.
Cells were then washed with binding buffer and fluorescence was
measured using a multimode plate reader (Ex 485 nm and Em 535
nm) (GENios Pro, Tecan, Milan, Italy). The values were normalized
on cell proliferation by Crystal Violet assay.
Analysis of intracellular ROS
The non-fluorescent diacetylated 2’,7’-dichlorofluorescein probe
(Sigma-Aldrich), which becomes highly fluorescent upon oxida-
tion, was used to evaluate intracellular ROS production by using a
multimode plate reader (GENios Pro, Tecan), as previously
described.25 To assess ROS production with flow cytometry, we
treated cells with 10 µM CM-H2DCFDA (Life Technologies, #C6827).
After re-suspending them in ice-cold fluorescence-activated cell
sorting-buffer (1% BSA in PBS), cells were immediately analyzed by
BD FACSCanto II (BD Bioscience, Franklin Lakes, NJ, USA) using the
488 nm blue laser and 530/30 nm filter. Unstained cells were used
to set dichlorofluorescein (DCF) fluorescent negative and positive
threshold.
To evaluate mitochondrial superoxide ion (O2ˉ·) production we
used the non-fluorescent MitoSox Red probe (Molecular Probes,
Eugene, OR, USA), as previously described.25 It is live-cell permeant
and is rapidly and selectively targeted to mitochondria where it
becomes fluorescent after oxidation by O2ˉ·, but not by other ROS
or reactive nitrogen species.
In melanoma cells, to analyze the H2O2 production level, the
Amplex Red Hydrogen Peroxide/Peroxidase Assay Kit (Molecular
Probes) was used. In brief, cells were seeded in 96-well plates
and at the end of cell treatments, 50 µM Amplex Red reagent
and 0.1 U/mL horseradish peroxidase were diluted in Krebs-
Ringer phosphate buffer and the mixture was added to the
cells. Fluorescence measurement was recorded at times 0, 15, and
30 min. An FLx800 microplate fluorescence reader (Bio-Tek,
Winooski, VT, USA) was used, set at Ex571 nm and Em585 nm.
Values were normalized on cell proliferation by Crystal Violet
assay.
Mitochondrial membrane potential determination
Mitochondrial membrane potential (ΔΨm) was measured fluor-
ometrically by using tetramethylrhodamine methyl ester (TMRM)
probe (Thermo Fisher Scientific). In brief, melanoma cells were
seeded in 96-well plates and, the next day, transfected with
control or p53 siRNA. After treatment, cells were incubated with
100 nM TMRM for 15min and fluorescence was measured in an
FLx800 microplate fluorescence reader (Bio-Tek) set at Ex552 nm
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and Em576 nm. Values were normalized per cell proliferation
determined by Crystal Violet.
Mitochondrial DNA damage analysis
Cells were seeded in six-well plates and the next day transfected
with control or p53 siRNA. After 48 h, cells were harvested with TRI
Reagent® (Sigma-Aldrich) and DNA was isolated according to
manufacturer’s instructions. Mitochondrial DNA (mtDNA) damage
was evaluated using a qPCR approach, amplifying a GC-rich region
of the mtDNA. The G nucleotide is usually the first to get oxidized,
and the PCR efficiency diminishes when mtDNA damage exists.
Two sets of primers were used, specified in Supplementary
Table 1. One of them amplifies a short fragment near the GC
region, and the other amplifies a long fragment, which includes
both the short fragment and the GC region, and is more sensitive
to oxidative damage. Damage in mtDNA is estimated by
calculating the ratio of long fragment/short fragment crossing
points.
MitoTracker and MitoSox colocalization analysis
For live cell imaging measurements, AsPC-1 cells/chamber were
seeded on a four-chamber µslide, with 13 mm glass bottom (ibidi
GmbH, Germany). After 24 h cells were transfected with pcDNA3-
mutp53R175H, pcDNA3-mutp53R273H or the pcDNA3 empty
vector (mock) by using LipofectamineTM2000 according to the
manufacturer’s instructions. Forty-eight hours after transfection
cells were incubated for 30minutes with a staining solution made
of MitoSox Red 1:1000 (Life Technologies) and Mitotracker Green
1:5000 (Life Technologies) in medium without FBS. Before the
acquisition, the medium was replaced with a special medium
without red phenol (DMEM/F12 NoPhenolRED, Life Technologies)
to avoid any interference with the fluorescence signal. Cell images
were captured using a confocal laser-scanning fluorescence
microscope Leica SP5 (Leica Microsystem, Manheim, Germany)
at × 63 magnification and processed using Adobe Photoshop and
ImageJ softwares (Rasband, W.S., ImageJ, U. S. National Institute of
Health, Bethesda, Maryland, USA (http://rsb.info.nih.gov/ij/,
1997–2008).
Glutathione content quantification
The intracellular glutathione (GSH) concentration was measured
by endpoint spectrophotometric titration method as previously
described.26 In brief, treated and untreated cells were lysed by
freezing and thawing in 100 mM sodium phosphate buffer, pH 7.5,
containing 5mM EDTA (KPE buffer) and after centrifugation at
16,000 rpm for 10 minutes, total protein concentration was
determined by using Bradford method. The supernatants were
deproteinized with 5% trichloroacetic acid. For GSH measurement,
acidified clear supernatants were neutralized and buffered at pH
7.4 with 200 mM K2HPO4, pH 7.5. The reaction was then started by
the addition of 60 µM Ellman’s Reagent [(5,5′-dithio-bis-(2-
nitrobenzoic acid)] and increase in absorbance at 412 nm was
measured until no variation in absorbance was evident. The
amount of total GSH was determined by comparison with GSH
standard curve.
Chronic lymphocytic leukemia (CLL) patients
Clinical annotations of 26 patients at diagnosis were collected for
time-to-first treatment (TTFT) curve analysis. Diagnosis was based
on 1996 National Cancer Institute-Working Group/IWCLL and 2008
Guidelines for Diagnosis and Treatment of CLL.27 Patient inclusion
criteria were the availability of mutational status of TP53 gene and
clinical annotation and the lack of treatment prior to sample
collection. Moreover, inclusion criteria for the TP53-wild-type
(TP53-wt) group were the lack of any cytogenetic anomaly.
Characteristics of patients at diagnosis are summarized in Table 2.
Patients were stratified into major cytogenetic categories, based
on NCCN CLL Guidelines28: favorable (del13q as a sole aberration),
neutral (normal karyotype, trisomy 12), and unfavorable (11q and/
or 17p deletion). Peripheral blood mononuclear cell (PBMC)
samples from 7 of 26 untreated CLL patients (4 with TP53-wt
and 3 with TP53-mut) were collected and cryopreserved at the
Hematology Unit, Azienda Ospedaliera Universitaria Integrata
(AOUI) in Verona (Italy) on approval from the local Ethics
Committee (Comitato Etico per la Sperimentazione, AOUI). In
accordance with the Declaration of Helsinki, all patients and
donors provided written informed consent for the collection and
use of their blood samples and clinical annotation for research
purposes.
CLL cell preparation
PBMCs were isolated by Ficoll-hypaque centrifugation (Lympho-
prep, Nicomed, Oslo, Norway) and stored in liquid nitrogen. Upon
thawing, only samples with at least 85% viability, assessed using 7-
amino-actinomycin dye (BD Biosciences, San Jose, CA, USA) and
flow cytometry (FACSCanto II, Becton Dickinson), were processed
further. CLL cells from samples with < 70% B cells were isolated by
negative selection using Human B-Cell Enrichment Kit (Stem Cell
Technologies, Vancouver, Canada). After separation, cell purity was
routinely above 98%, as assessed with CD19 staining and flow
cytometry (FACSCanto II, Becton Dickinson).





Total, n Total, n
Age at the diagnosis
median (range), years 63 (43–81) 70 (52–85)
Gender
male 9 (56%) 6 (60%)
female 7 (44%) 4 (40%)
Stage
Binet A 16 (100%) 9 (90%)
Binet B 0 (−) 1 (10%)
Binet C 0 (−) 0 (−)
IGHVa
Mutated 16 (100%) 2 (20%)
Unmutated 0 (−) 7 (70%)
NA – 1 (10%)
CD38b
Negative 16 (100%) 4 (40%)
Positive 0 (-) 6 (60%)
Cytogenetics
Favorable 0 (-) 2 (20%)
Neutral 16 (100%) 3 (30%)
Unfavorable 0 (−) 3 (30%)
NA – 2 (20%)
Follow-up
Median (range), years 4 (1–6) 5 (2–19)
Disease progression, requiring
treatment during follow-up
2 (13%) 7 (70%)
TTFT
Median (range), months 14 (7–22) 49 (3–212)
NA not available
aIGHV sequencing utilized a 2% cutoff to discriminate mutated from
unmutated IGHV
bCD38 was determined using a 30% cutoff
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Genetic analysis
Cytogenetic abnormalities were evaluated by cytogenetic and
fluorescence in situ hybridization (FISH), according to the
hierarchical risk model of FISH anomalies.29 The mutation hot-
spots of the TP53 (exons 4–9, including splicing sites; RefSeq
NM_000546.5) gene were analyzed by PCR amplification and
direct sequencing of high molecular weight genomic DNA, as
previously described.30
Reduced thiols
Levels of reduced thiols were detected by ThiolTracker Violet
(Thermo Fisher Scientific), according to the manufacturer’s
instruction. In brief, final 5 μM ThiolTracker was added to cell
suspension and incubated at 37 °C for 30minutes. After incuba-
tion, cells were stained with anti-CD19-APC and anti-CD5-PECy7
(BD Biosciences) for 15 minutes and analyzed by flow cytometry
(FACSCanto II, Becton Dickinson). Analysis was gated on CLL cells,
identified as CD19/CD5 co-expressing cells.
Statistical analysis
Analysis of variance analysis with GraphPad Prism 5 software or
two-tailed t test were used to calculate P values. Statistically
significant results were referred with a P value < 0.05. Values are
the means of three independent experiments ( ± SD). In CLL
patients, TTFT was calculated from the date of diagnosis to the
date of initial therapy.27 Patients who did not receive any
treatment during follow-up were censored at their last follow-up
date. TTFT curves estimated using the Kaplan–Meier method were
compared using the log-rank (Mantel–Cox) test.
RESULTS
Mutant p53 increases mitochondrial ROS production
To study the functional role of GOF mutant p53 proteins in the
regulation of ROS production, we first analyzed the endogenous
level of ROS by staining diverse cancer cell lines with the DCF
probe. Cancer cells with different missense mutations of the TP53
gene (Table 1) had the endogenous level of ROS significantly
higher than cells with wild-type TP53 alleles in both pancreatic
and breast cancer cell lines (Supplementary Figure 1), suggesting
a possible involvement of mutant p53 in the production of ROS.
When PaCa3 and MCF7 cell lines (expressing wtp53 protein) were
knocked down for p53 expression by using liposome-mediated
transient transfection assay, the ROS level increased, accordingly
with the well-described antioxidant role of wild-type p53 (Fig. 1a).
Conversely, the ROS level was significantly decreased after
knockdown of GOF mutant p53 in Panc1, MDA-MB-468, and
SkBr3 cancer cell lines (Fig. 1a). Consistent with this, exogenous
overexpression of R175H or R273H mutant p53 proteins in
AsPC1 cells (null for p53 expression) produced a drastic increase
of ROS level (Fig. 1a). We further strengthened these data
through lentivirus-mediated transduction and DCF fluorescence
analysis by flow cytometry using two different sequences to
knockdown mutant p53 expression (p53-SH1 or p53-SH2) or their
negative control (p53-NT) in breast cancer MDA-MB-231 cells
(Fig. 1b). Altogether these data finally confirm the pro-oxidant
role of mutant p53 isoforms in pancreas and breast cancer cell
lines. We also observed that intracellular GSH concentration
increased after mutant p53 gene silencing, whereas it decreased
after wild-type p53 downregulation (Fig. 1c), further supporting
the pro-oxidant role of mutant proteins. These data highlight the
opposite role of the tumor suppressor wild-type p53 and mutant
p53 isoforms on the regulation of the intracellular redox status of
cancer cells.
In the last few years, screening approaches have led to the
identification of small molecules, such as CP-31398 and RITA,
which can re-establish the wild-type transcriptionally competent
conformation of mutant p53 proteins. These molecules are able to
activate the wild-type-like p53 function in cancer cells expressing
mutant proteins, triggering p53-dependent tumor suppres-
sion.31,32 Figure 1d shows that treatment with the p53-
reactivators CP-31398 or RITA decreased ROS level in both cancer
cells having wild-type p53 (PaCa3) and mutant p53 (Panc1);
whereas ROS level in p53-null AsPC1 cells was unaffected by these
compounds, suggesting that p53 expression is required for their
action. These results confirm the antioxidant role of wild-type p53
and further indicate that the mutp53-depedent pro-oxidant
function can be reverted by activating the wild-type-like
conformation of the protein.
To further investigate the subcellular source of ROS production
by mutant p53 we analyzed mitochondrial superoxide ions (O2ˉ·)
by using MitoSox Red probe. We markedly observed fluorescence
emitted by MitoSox Red probe after exogenous overexpression of
R175H or R273H mutant p53 isoforms in p53-null AsPC1 cells
(Figs. 1e, f) and also a strong colocalization of the fluorescence
signals by MitoSox Red probe (revealing mitochondrial superoxide
ions) and by MitoTracker Green (staining mitochondria) (Fig. 1e).
These results indicate that mitochondria are a crucial source of
ROS production induced by mutant p53 isoforms.
The induction of ROS is functionally involved in the oncogenic
effects of mutant p53
To explore the role of ROS stimulation on the oncogenic effects of
mutant p53 isoforms in cancer cells we analyzed cell proliferation,
apoptosis, and response to GEM after addition of the radical
scavenger NAC. First, we demonstrated that this antioxidant
molecule was able to successfully counteract ROS production by
overexpression of R175H or R273H mutant p53 isoforms in p53-
null cells (Fig. 2a). The hyper-proliferative effect induced by
mutant p53 was also completely reversed by NAC treatment
(Fig. 2b). Furthermore, we demonstrated that the antiapoptotic
effect induced by overexpression of mutant p53 isoforms was
completely counteracted by NAC (Fig. 2c), demonstrating the
functional involvement of ROS on these oncogenic events. As we
previously published that mutant p53 conferred chemoresistence
to GEM treatment in pancreatic cancer cells,10 we investigated
whether this function may be mediated by ROS. Figure 2d shows
that chemoresistance, observed after GEM treatment in the
presence of mutant p53 overexpression, as compared with
gemcitabine and mock conditions, was totally counteracted by
the addition of NAC. By a therapeutic point of view, it is known
that increasing ROS beyond a threshold level can inhibit cell
proliferation inducing cell death, so we investigated whether
cancer cells expressing mutant p53 may acquire sensitivity to pro-
oxidant agents. As shown in Fig. 2e, expression of R273H mutant
p53 enhances cancer cell sensitivity to hydrogen peroxide,
reversing the hyper-proliferative effect induced by mutant p53
and suggesting oxidant therapeutics in the treatment of cancer
cells bearing mutant TP53 gene. Concerning the clinical relevance
of these data, we hypothesized that the presence of mutant TP53
gene may have an impact on both the clinical outcome of CLL
patients and in their oxidant status. Importantly, all CLL samples
were collected at the time of diagnosis and therefore no
treatment was performed on the CLL patients analyzed. As
expected, we observed that TP53 gene mutation was associated
with a faster clinical progression in CLL (P= 0.0259), as shown by a
shorter TTFT in Kaplan–Meier curves (Fig. 2f). Remarkably,
leukemic patients harboring mutant TP53 gene display also lower
levels of reduced thiols (P= 0.0481), the major non-enzymatic
antioxidant scavenger (Fig. 2g). Moreover, we sub-classified the
CLL samples based on the p53 mutation types reported in
Supplementary Table 2 and we analyzed TTFT of different
patients’ subgroups. We observed a significant acceleration of
the clinical progression in frameshift mutant TP53 gene CLL
patients as compared with WTp53 CLL, while missense mutants
show a marked trend of faster clinical progression as compared
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Fig. 1 Mutant p53 proteins enhance ROS production in cancer cells. a The indicated cell lines were seeded in 96-well plates, incubated
overnight, and transfected with the pRSuper-p53 vector and with plasmids for overexpression of mutant p53 (o.e. R175H; o.e. R273H), or their
relative negative mock control (CTRL). DCF fluorescence intensity was analyzed by a multimode plate reader. Western blot of p53 was
performed to test the effective knockdown of WT or mutant p53 and the overexpression of mutant p53 in the various cell lines indicated.
b MDA-MB-231 cells stably silenced for p53 by lentiviral transduction with two different short hairpin sequences, were treated for 15min with
the ROS probe CM-H2DCFDA and then analyzed by FACS. Bars represent average (± SEM) of the percentage of DCF positive (+) cells measured
by FACS from two independent biological experiments performed in technical duplicate. Statistically significant differences are indicated: *p <
0.05, ** p < 0.001. Western blot of p53 was performed to test the effective knockdown of mutant p53. c The intracellular oxidized and reduced
glutathione were determined in MCF7 and Panc1 mutR273H-p53 cell lines after transient transfection with the pRsuper-p53 vector. d The
indicated cell lines were seeded in 96-well plates, incubated overnight, and treated with 20 µM CP-31398 or 40 µM RITA for 48 h. DCF
fluorescence intensity was measured by a multimode plate reader. e Live cell imaging: 48 h after transfection with plasmid coding for R175H
or R273H mutant p53, or with the mock vector (CTRL), cells were incubated for 30min with MitoSox probe (red) and Mitotracker Green
(green). The RGB profile plotted along the dashed line drawn in the merge image is also shown. Merge and single channel images come from
a single z-plane. Scale bar 10 μm. f Mitochondrial superoxide evaluation by MitoSox Red probe was analyzed with a multimode plate reader.
Cells were seeded in 96-well plates, incubated overnight, and transfected with plasmid coding for R175H or R273H mutant p53, or the mock
vector. All the experiments presented in this figure are representative of three biological replicates. P values were calculated with two-tailed t
test. Statistical analysis: *p < 0.05
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with WTp53 CLL (Supplementary Figure 2). We also observed a
significant acceleration of the clinical progression in exon 5–6
mutant TP53 gene CLL patients as compared with WTp53 CLL,
whereas exon 7 mutants show a strong trend of faster clinical
progression as compared with WTp53 CLL (Supplementary
Figure 2). Overall, all subgroups tested of CLL patients bearing
mutant TP53 gene show a worsening of the clinical outcome as
compared with WTp53 CLL patients. These data might be further
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Fig. 2 ROS induced by mutant p53 proteins are critical to mediate their oncogenic proprieties. a, b, c AsPC1-p53 null cells were transfected
with R175H or R273H vector, or mock control, and concomitantly treated with 7mM NAC for 24 h. a Intracellular ROS level was evaluated
analyzing DCF fluorescence intensity using a multimode plate reader. b Cell proliferation was measured by Crystal Violet assay and c apoptosis
was determined by the annexin V/FITC binding assay. Statistical analysis: *p < 0.05; P values were calculated with two-tailed t test. R175H vs
R175H+NAC and R273H vs R273H+NAC. d AsPC1-p53 null cells were transfected with R175H and R273H vector, or negative control, and
concomitantly treated with 7mM NAC and 1 µM GEM for 24 h. Cell proliferation was measured by Crystal Violet assay. Statistical analysis: *p <
0.05; P values were calculated with two-tailed t test. R175H+ GEM vs R175H+NAC+ GEM and R273H+ GEM vs R273H+NAC+ GEM.
e AsPC1-p53 null cells were transfected with mock vector or with vector to express R175H mutant p53. After 24 h cells were treated with 100
µM H2O2 for further 24 h. Cell proliferation was measured by Crystal Violet assay. Statistical analysis: *p < 0.05 or ** p < 0.01 P value were
calculated with two-tailed t test. R175H vs mock. f Kaplan–Meier curves of TTFT for CLL patient subgroups defined by mutational status of
TP53 gene: wild-type (TP53-wt; n= 16) or mutated (TP53-mut; n= 10). g Comparison of reduced-thiol levels (detected by ThiolTracker probe)
between CLL patients harboring TP53 gene wild-type (TP53-wt; n= 4) or mutated (TP53-mut; n= 3). Statistical analysis was performed using
the Student’s t test. Data are expressed as mean ± SEM. *: P < 0.05
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Mutant p53 downregulates UCP2 expression through the
inhibition of PGC-1α
As mitochondrial uncoupling protein UCP2 represents the first
mechanism able to counteract the electron leakage from the
respiratory chain and, in turn, to decrease the superoxide ions
production in mitochondria, we investigated whether mutant p53
can modulate UCP2 expression and its transcriptional activator,
peroxisome PGC-1α. Indeed, UCP2 expression is intimately linked
to the activity of PGC-1α33 and PGC-1α/UCP2 axis is recognized as
a relevant player in the maintenance of the mitochondrial redox
balance.19,34 Herein, we observed that the depletion of endogen-
ous mutant p53 in Panc1 cells determined the induction of both
PGC-1α and UCP2 mRNAs, whereas the exogenous expression of
the R273H mutp53 isoform inhibited their expression in p53-null
AsPC1 (Fig. 3a). We further confirmed the mutp53-dependent
stimulation of ROS associated to the downregulation of PGC-1α
and UCP2 mRNAs in a clone of lung carcinoma H1299 cells stably












































































































































































































































Fig. 3 Mutant p53 downregulates UCP2 and PGC-1-α. a Panc1 mutR273H-p53 and AsPC1-p53 null cells were transfected with pRSuper-p53
vector and with plasmids for the ectopic expression of mutant p53-R273H or its relative negative control (CTRL). Gene expression analysis of
the p53, UCP2, and PGC-1α was performed by RT-qPCR and was normalized to GAPDH mRNA. *p < 0.05. b H1299 p53-null cells stably
expressing p53-R273H (clone H1) and respective mock control (clone C9) were used to analyze PGC-1α and UCP2 expression by RT-qPCR,
normalized to GAPDH mRNA, and ROS levels with DCF probe. The western blotting was performed using 50 μg of whole-cell extracts and
probed with p53 and vinculin antibodies *p < 0.05. c Panc1 mutR273H-p53 and AsPC1-p53 null cells were treated with 40 µM RITA and 20 µM
CP-31398 for 48 h and gene expression analysis of UCP2 was performed by RT-qPCR and normalized to GAPDH mRNA. *p < 0.05. d Western
blotting analysis of Panc1 mutR273H-p53 and AsPC1-p53 null cells transfected with the indicate plasmids. Western blotting was performed
using 50 μg of whole-cell extracts, probed with the indicated antibodies and quantified with ImageJ software. e Panc1 mutR273H-p53 cells
were transfected with pRSuper-p53 vector and siRNA-PGC-1α and relative controls and gene expression analysis of UCP2 was performed by
RT-qPCR and normalized to GAPDH mRNA. *p < 0.05 shCTRL vs shp53; #p < 0.05 shp53 vs shp53+ siPGC-1α. The experiments are
representative of three biological replicates
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In accordance with the repressive effect of mutant p53 on the
PGC-1α/UCP2 axis, the p53-reactivators CP-31398 or RITA
increased the expression level of UCP2 mRNA in mutant p53
Panc1 cells, whereas failed to modulate UCP2 expression in p53-
null AsPC1 cells, used as negative control (Fig. 3c). We also
demonstrated at the protein level the inhibitory role of mutant
p53 on the expression of PGC-1α and UCP2 in Panc1 and
AsPC1 cells (Fig. 3d). Notably, Fig. 3e shows that the stimulation of
UCP2 mRNA by mutp53 knockdown was completely counteracted
by co-transfecting Panc1 cells with siRNA-PGC-1α, demonstrating
the functional involvement of PGC-1α inhibition in the repression
of UCP2 mRNA by mutant p53.
UCP2 inhibition by mutant p53 increases ΔΨm without damaging
mtDNA
To confirm these observations also in other tumor types we
downregulated p53 expression in both A375 melanoma cells,
bearing wild-type p53, and MeWo melanoma cells, bearing E258K
mutant p53, and analyzed ROS and UCP2 levels. Figure 4a shows
that mutant p53 silencing decreased H2O2 production and
increased UCP2 mRNA expression, whereas wild-type
p53 silencing did not affect H2O2 production and only slightly
decreased UCP2 mRNA. At the protein level, we obtained similar
results (Fig. 4b), confirming also in melanoma cells that the UCP2-
mediated pro-oxidant effect is a phenomenon acquired by mutant
p53 isoforms. Furthermore, we analyzed the ΔΨm and mtDNA
damage after knockdown of p53 expression in both cell lines.
Figure 4c shows that ΔΨm decreased after mutant p53 silencing,
whereas there were no changes in mtDNA damage. Overall these
data suggest that mutp53-dependent UCP2 inhibition determined
mitochondrial superoxide production and hyperpolarization with-
out damaging mtDNA.
Mutant p53-dependent downregulation of the PGC-1α/UCP2 axis
is mediated by the blockage of SESN1/AMPK signaling
As AMPK signaling pathway has a crucial role in many biological
functions, including the induction of PGC-1α, we examined whether
mutant p53 might inhibit PGC-1α/UCP2 axis through the upstream
blockage of AMPK. We demonstrate that R273H mutant p53
inhibited the level of SESN1 and SESN2 mRNAs (Supplementary
Figure 3) and that knockdown of R280K mutant p53 increased the
protein expression of SESN1 and SESN2, as well as the phospho
tyrosine-172 AMPK level without affecting the total amount of
AMPK expression (Fig. 5a), as previously observed also for R175H
and R273H mutant p53 isoforms,15 suggesting that the inhibition of
SESNs and of AMPK signaling is a common event triggered by
various hotspot mutant isoforms of p53. Importantly, we demon-
strated by immunoprecipitation that SESN1-AMPK binding
increased in R280K mutant p53 silencing conditions, likely as a
consequence of SESN1 increase (Fig. 5a). This result is in accordance
with the enhanced level of P-AMPK as SESN1:AMPK complex favors
AMPK phosphorylation by upstream kinases.35 Figure 5a also shows
that the formation of SESN2:AMPK complex was not regulated by
mutant p53, despite mutant p53 inhibited the expression of SESN2,
further improving the findings about SESN1:AMPK complex. To
confirm the results shown in Fig. 5a, we used a clone of p53-null
H1299 cells stably expressing R273H mutant p53 and its mock
control clone. Figure 5b shows that expression of R273H mutant
p53 decreased the protein expression of SESN1 and SESN2, as well
as the P-AMPK level without affecting the total amount of AMPK
expression. We also demonstrated by reciprocal SESN1 immuno-
precipitation assay that R273H mutant p53 decreased SESN1
expression and, consequently, SESN1 binding to AMPK.
To investigate the functional role of AMPK signaling in the
inhibition of PGC-1α/UCP2 axis by mutant p53, we treated cells
with AICA-R, a chemical activator of AMPK (Supplementary
Figure 4). Figure 5c shows that the repression of both PGC-1α
and UCP2 mRNAs by overexpression of mutant p53 was reverted
by AICA-R. In addition, we further demonstrated that transfection
with a DN isoform of AMPK γ, as compared with transfection with
wild-type AMPK isoform γ (WT-AMPK), was able to significantly
counteract the induction of both PGC-1α and UCP2 mRNAs after
silencing of endogenous mutant p53 (Fig. 5d). Altogether these
data indicate that mutp53-dependent downregulation of the PGC-
1α/UCP2 axis is mediated by the blockage of AMPK signaling.
In order to investigate whether AMPK also plays a role in the
final pro-oxidant effect of mutant p53, we analyzed ROS level after
silencing endogenous mutant p53 with the concomitant transfec-
tion of DN-AMPK or WT-AMPK. Figure 5e shows that ROS level
decreased in mutp53-knockdown conditions and it was recovered
by DN-AMPK. Altogether these data indicate that the pro-oxidant
inhibition of the PGC-1α/UCP2 axis by mutant p53 is functionally
owing to the AMPK signaling inhibition, which might be, at least
partially, ascribed to the inhibition of SESN1 expression.
UCP2 blockage has a major role on the pro-oxidant and oncogenic
effect of mutant p53
To functionally demonstrate that the UCP2 blockage has a role on
the pro-oxidant effect of mutant p53, we used the known UCP2
inhibitor genipin,25 or modulated UCP2 expression by siRNA or
exogenous overexpression as checked in Supplementary Figure 5.
In Fig. 6a we demonstrated that ROS level decreased after mutant
p53 knockdown was recovered by siRNA-UCP2 or by genipin in
Panc1 cells. In addition, ROS level increase by R273H or R175H
mutant p53 overexpression in p53-null AsPC1 cells was counter-
acted by UCP2 overexpression (Fig. 6a). In accordance with the
observation that mitochondria represent a main source of ROS by
mutant p53 we observed similar results analyzing mitochondrial
superoxide ions (Fig. 6b). To finally demonstrate that UCP2
inhibition is involved in the oncogenic hyper-proliferative effect of
mutant p53 we analyzed cancer cell proliferation after the
concomitant silencing of mutant p53 and UCP2. Figure 6c reveals
that UCP2 knockdown was able to partially reverse the
antiproliferative effect of mutant p53 blockage. Altogether these
data indicate that UCP2 inhibition is a mechanism by which
mutant p53 isoforms exert their oncogenic pro-oxidant functions.
PGC-1α/UCP2 axis is not regulated by the endogenous basal level
of wild-type p53
To confirm that PGC-1α/UCP2 inhibition is specifically a mutant
p53-related GOF mechanism we examined whether the endo-
genous basal level of wild-type p53 is able to modulate this axis.
Figure 7a shows that in PaCa3 cells wild-type p53 knockdown
failed to modulate both mRNA and protein expression levels of
PGC-1α, a crucial transcriptional activator of the UCP2 gene. In
addition, wild-type p53 knockdown also failed to modulate UCP2
mRNA and protein expression levels (Fig. 7a), in accordance with
the lack of PGC-1α regulation and the absence of p53 binding
sequences in the regulatory regions of the UCP2 gene. As it has
been described that mutant p53 can bind to wild-type p53 as
heterodimers acting as dominant negative regulators of wtp53
functionality,36 we expressed the R175H mutp53 isoform in PaCa3
cells bearing wild-type TP53 gene. Supplementary Figure 6 shows
that R175H mutp53 increased ROS, in accordance with the
suppression of the antioxidant role of wtp53, without altering
the expression level of PGC-1α and UCP2. These data further
confirm the statement that PGC-1α/UCP2 axis is not regulated by
endogenous basal level of wtp53 and its inhibition is a mutp53-
related GOF mechanism.
Chemotherapy stimulates UCP2 through wtp53 activation
As wild-type p53 generally needs stimulation to become active,
we triggered wild-type p53 phosphorylation by treating pancrea-
tic cancer PaCa3 cells with the chemotherapeutic drug GEM.
Figure 7b shows that GEM was able to induce P-p53, P-AMPK and
UCP2, suggesting that, once activated, wild-type p53 might induce
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the antioxidant AMPK/UCP2 axis, in accordance with its anti-
oxidant and tumor suppressive functions. To investigate the
functional involvement of wild-type p53 in the UCP2 stimulation
by GEM, we analyzed UCP2 and p53 mRNAs after p53 silencing
and GEM cell treatment. Figure 7c shows that wild-type p53
knockdown decreased GEM-mediated induction of UCP2 mRNA.
Altogether these data indicate that the AMPK-meditated pro-
oxidant UCP2 inhibition is a mechanism linked to GOF mutant p53
and not to the endogenous basal level of wild-type p53, which on
the contrary, upon activation, may promote the expression of the
antioxidant UCP2 gene, likely through the AMPK signaling.
A schematic representation of the molecular mechanisms
identified in this study is provided in Fig. 7d. Overall, it emerges
that wild-type and mutant p53 have an opposite regulation of
mitochondrial ROS and that this dual effect is based on the
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Fig. 4 Mutant p53 increases ΔΨm without damaging mtDNA. a Melanoma cell lines A375 (WTp53) and MeWo (mutant p53) were transfected
with control or siRNA-p53. H2O2 production was evaluated with the Amplex Red Kit, whereas UCP2 and p53 levels were determined by RT-
qPCR. *p < 0.05. b Protein expression analysis of p53 and UCP2 was performed by western blotting and normalized to GAPDH expression. *p <
0.05. c Mitochondrial membrane potential (ΔΨm) was determined by TMRM fluorescencent probe, and mtDNA damage was evaluated with a
qPCR approach as described in Material and Methods section. *p < 0.05 CTRL vs siRNA-p53. The experiments are representative of three
biological replicates
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DISCUSSION
ROS are persistently elevated in cancer cells as a consequence of
increased metabolic activity, mitochondrial dysfunction, and
activation of oncogenes.37 Some studies unveil that ROS play
exceptional relevance in the development and progression of
tumors being involved in the main features of aggressive cancer
cell behavior, including genome instability, cellular hyper-pro-
liferation, epithelial–mesenchymal transition, invasion, and metas-
tasis.38 However, the role of ROS in cancer cell biology is highly
contextual and dependent on the nature of the stress, tumor
tissue, and stage.39 Indeed, despite they can stimulate tumorigen-
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Fig. 5 Mutant p53 inhibits UCP2 and PGC-1α through the inhibition of SESN1/AMPK signaling. a MDA-MB-231 cells were transduced with
lentiviruses containing p53-SH1 or p53-SH2 vectors for mutant p53 silencing or their non-targeting negative control (NT). Left panel: western
blotting was performed using 50 μg of whole-protein extracts and probed with the indicated antibodies. The p53 expression was shown as
control of p53 knockdown efficacy and the GAPDH expression was used as control of equal proteins loading. Right panel: AMPK was
immunoprecipitated from protein extracts using anti-rabbit AMPK antibody (IP: AMPK) and western blot analysis was performed using
indicated antibodies. Protein extracts from cells silenced for p53 expression with p53-SH1 or p53-SH2 vectors were also immunoprecipitated
with rabbit IgG as control. The blot exhibits equivalent AMPK levels in all samples. b H1299 p53-null cells stably expressing R273H mutant p53
(clone H1) and its respective mock control (clone C9) were used to confirm the regulation of SESN1:AMPK by mutant p53. Left panel: western
blotting was performed using 50 μg of whole-protein extracts and probed with the indicated antibodies. Right panel: SESN1 was
immunoprecipitated from protein extracts using anti-SESN1 antibody (IP: SESN1) and western blot analysis was performed using indicated
antibodies. Protein extracts were also immunoprecipitated with IgG as control. c AsPC1-p53 null cells were transfected with the vectors for the
ectopic expression of p53-R273H and its mock control and treated with 1 mM AICA-R for 48 h. Gene expression analysis of the UCP2 and PGC-
1α was performed by RT-qPCR and normalized to GAPDH mRNA. #p < 0.05 mock vs mock+ AICA-R; *p < 0.05 mock vs R273H and R273H vs
R273H+ AICA-R. d Panc1 mutR273H-p53 cells were transfected for 48 h with the indicated vectors and their relative negative controls. Gene
expression analysis of UCP2 and PGC-1α was performed by RT-qPCR and normalized to GAPDH mRNA. *p < 0.05 shp53 vs CTRL; #p <
0.05 shp53+DN-AMPK vs shp53 or shp53+WT-AMPK. e The indicated cell lines were transfected with pRSuper-p53, DN-AMPK, WT-AMPK
vectors, or negative controls. ROS levels were analyzed using DCF probe by a multimode plate reader. *p < 0.05 shp53 vs CTRL; #p <
0.05 shp53+DN-AMPK vs shp53 or shp53+WT-AMPK. The experiments are representative of three biological replicates
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induce cell death following a non-specific injury of macromole-
cules and cellular organelles.40
It is emerging that mutant p53 proteins, contrarily to their wild-
type p53 counterpart, fail to exert antioxidant properties rather
sustaining a controlled increase of intracellular ROS, resulting in
cancer progression. In accordance with this statement, we recently
demonstrated that mutant p53 inhibits the expression of sestrins,15
which are a family of highly conserved stress-inducible proteins and
important negative regulators of both ROS and mTORC1 signaling
pathways.41 The antioxidant effect of sestrins mainly occurs
stimulating the p62-dependent autophagic degradation of the
protein Keap1, an inhibitor of the crucial antioxidant transcription
factor NRF2,42 and through its intrinsic peroxidase activity.41 In
addition, sestrins can attenuate ROS accumulation by blocking
mTORC1 activation. This inhibition of mTORC1 activity is achieved
either via the AMPK-dependent phosphorylation and activation of
TSC2 and consequent inhibition of the GTPase Rheb or via
inhibition of the GTPase Rag and consequent prevention of the
lysosomal localization of mTORC1 triggered by amino acids.42
Beyond the inhibition of sestrins, Rotter and colleagues elucidated
that R273H mutant p53 interferes with the normal response of
tumor cells to oxidative stress being able to attenuate the
antioxidant function of NRF2.43 Furthermore, Boudreau et al.44
revealed that mutant p53 proteins, contrarily to the wild-type
counterpart, enhance the expression of the NADPH oxidase NOX4,
resulting in an increase of intracellular ROS levels, which sustain an
invasive phenotype of breast cancer cells. Khromova et al.
demonstrated that p53 hotspot mutants increase intracellular ROS
level determining the augmentation of the number of vessels in




































































































































































































Fig. 6 Mitochondrial superoxide production is due to mutp53-dependent UCP2 inhibition. a Panc1 mutR273H-p53 and AsPC1-p53 null cells
were transfected with pRSuper-p53 and vector for mutant p53 ectopic expression, respectively, and their relative controls. In addition,
Panc1 cells were co-transfected with siRNA-UCP2, or treated with 150 μM genipin for 24 h; while AsPC1 cells were co-transfected with the
UCP2 vector. ROS production, corresponding to DCF fluorescence intensity, was analyzed by a multimode plate reader. *p < 0.05 shCTRL vs
shp53 or mock vs R175H or R273H; #p < 0.05 shp53 vs shp53+ siUCP2 or shp53+ genipin (Panc1 cells); R175H or R273H vs R175H+ UCP2 or
R273H+UCP2 (AsPC1 cells). b AsPC1 cells were transfected with the vectors for UCP2 and/or mutant p53 expression. Mitochondrial
superoxide production was determined with the MitoSox Red probe by a multimode plate reader. *p < 0.05 CTRL vs R175H or R273H; #p < 0.05
R175H or R273H vs R175H+UCP2 or R273H+ UCP2. c Panc1 cells were transfected for 48 h with shp53 and/or siUCP2 and their relative
negative controls. Cell proliferation was measured by Crystal Violet assay. *p < 0.05 shCTRL vs shp53; shp53 vs shp53+ siUCP2. The
experiments are representative of three biological replicates
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growth. They revealed that the stimulation of tumor angiogenesis
occurs through ROS upregulation causing activation of HIF1/VEGF-A
pathway.45 More recently, some studies revealed that mutant p53
proteins suppress the expression of SLC7A11, a key component of
the cystine/glutamate antiporter system xC-, diminishing glu-
tathione synthesis and resulting in redox imbalance.46,47
In the present study, we demonstrate that various hotspot


































































































Fig. 7 Gemcitabine triggers WTp53 and UCP2 expression. a PaCa3 cells (WTp53) were transfected for 48 h with the pRSuper-p53 vector or its
relative negative control (shCTRL). Gene expression analysis of p53, UCP2, and PGC-1α was performed by RT-qPCR and normalized to GAPDH
mRNA. Protein expression analysis of p53, PGC-1α, UCP2, and GAPDH was performed by western blotting. *p < 0.05. b Western blotting
analysis of PaCa3 cells treated with 1 µM GEM for 24 h using 50 μg of whole-cell extracts and probed with the indicated antibodies. c PaCa3
cells were treated with 1 µM GEM for 24 h and/or transfected with the siRNA-p53 or its relative siRNA scramble (CTRL). Gene expression
analysis of UCP2 and p53 was performed by RT-qPCR and normalized to GAPDH mRNA. *p < 0.05 CTRL vs GEM or sip53; #p < 0.05 GEM vs
sip53+ GEM. The experiments are representative of three biological replicates. d Model of the mechanisms identified in the present study
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in a number of cancer cell lines from different tissue origins,
including pancreas, breast, skin, and lung. As we recently
published that low expression of the antioxidant gene catalase
confers redox hypersensitivity in CLL patients,48 we here
investigated the involvement of mutant p53 in the redox
regulation of CLL and we find a correlation between the poor
clinical outcome of CLL patients having mutant TP53 gene with a
decreased amount of intracellular reduced thiols. Overall, we
identify a novel mechanism by which mutant p53 proteins can
stimulate their oncogenic pro-oxidant conditions through the
inhibition of SESN1 expression and, consequently, of the SESN1:
AMPK complex amount, resulting in the downregulation of the
PGC-1α/UCP2 axis. AMPK is considered a master regulator of
cellular metabolism and it has been shown to control the
expression of several mitochondrial enzymes and proteins,49
including PGC-1α, which has been widely described to act as
master regulator of mitochondrial biogenesis.50 Previous work has
demonstrated that PGC-1α can function as a regulator of its own
gene expression in a feedforward loop.51 More recently, Jager
et al.52 demonstrated that AMPK directly phosphorylates PGC-1α
at threonine-177 and serine-538 and that these phosphorylations
are required for the PGC-1α-dependent induction of the PGC-1α
promoter, indicating that AMPK phosphorylation of PGC-1α
initiates many of the important gene regulatory functions of
AMPK. Mechanistically, these AMPK-mediated phosphorylations
might modulate the ability of PGC-1α to dock on certain
transcription factors or affect the binding or function of other
cofactors in the PGC-1α coactivator complex. PGC-1 family
members of transcription coactivators can stimulate the expres-
sion of mitochondrial uncoupling proteins, as UCP2 and UCP3.53 In
particular, UCP2 expression is intimately linked to the activity of
the PGC-1α and in pancreatic beta-cells, PGC-1α has been shown
to stimulate UCP2 gene expression via binding to two proximal
regions of the UCP2 promoter.33
In addition to the antioxidant property of UCP2 by allowing the
flux of protons from the intermembrane space to the mitochon-
drial matrix, the channel formed by uncoupling proteins can also
promote the mitochondrial efflux toward the cytosol of pyruvate
and of Krebs cycle intermediates, regulating glucose and
glutamine oxidation.54 We have recently found that UCP2 also
induces the expression of GLUT1 and pyruvate kinase isoform
M2 sustaining the glycolytic phenotype of pancreatic adenocar-
cinoma cells.55 Therefore, the PGC-1α/UCP2 axis not only has
mere antioxidant properties, but also has a central role in
regulating the energetic metabolism of the cells. Then, our study
also provides the molecular basis for future metabolic studies that
might further clarify the alterations of cancer metabolism driven
by mutant p53.
In conclusion, it is conceivable that GOF mutant p53 isoforms
contribute to enhance ROS levels in cancer cells through a
coordinated regulation of redox-related enzymes and signaling
pathways, including SESN1/AMPK/PGC-1α/UCP2 axis, favoring
cancer cell growth without damaging mitochondria. As ROS can
produce genomic DNA damage,56 it is conceivable that ROS
enhancement by mutant p53 may contribute to the induction of
genomic DNA damage and genomic instability, which are typical
hallmarks of cancer cells bearing mutant TP53 gene.8,57 Intrigu-
ingly, from a therapeutic point of view, the intracellular ROS
enhancement driven by mutant p53 might represent an “Achilles
heel” of cancer cells carrying mutant TP53 gene, as revealed by the
mutp53-dependent acquisition of cell sensitivity to H2O2 treat-
ment. These results suggest that cancer cells expressing mutant
p53 proteins can be significantly more sensitive to pro-oxidant
drugs, as compared with the wild-type counterpart, leading to
overwhelming ROS accumulation and cancer cell death. This
might provide new therapeutic opportunities to be further
considered for clinical studies in cancer patients bearing mutant
TP53 gene.
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